Myelo Therapeutics

Myelo Therapeutics GmbH develops innovative therapies in areas of unmet medical need. Its lead compound, myelo001, is a small molecule effective in hematopoiesis. Its oral application is under investigation for: chemotherapy-induced myelosuppression (CIM), including chemotherapy-induced neutropenia (CIN), chemotherapy-induced thrombocytopenia, and chemotherapy-induced lymphopenia; radiation-induced myelosuppression (RIM); and acute radiation syndrome (ARS).